341 related articles for article (PubMed ID: 22909342)
1. Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients.
Ellebaek E; Iversen TZ; Junker N; Donia M; Engell-Noerregaard L; Met Ö; Hölmich LR; Andersen RS; Hadrup SR; Andersen MH; thor Straten P; Svane IM
J Transl Med; 2012 Aug; 10():169. PubMed ID: 22909342
[TBL] [Abstract][Full Text] [Related]
2. Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2.
Nguyen LT; Saibil SD; Sotov V; Le MX; Khoja L; Ghazarian D; Bonilla L; Majeed H; Hogg D; Joshua AM; Crump M; Franke N; Spreafico A; Hansen A; Al-Habeeb A; Leong W; Easson A; Reedijk M; Goldstein DP; McCready D; Yasufuku K; Waddell T; Cypel M; Pierre A; Zhang B; Boross-Harmer S; Cipollone J; Nelles M; Scheid E; Fyrsta M; Lo CS; Nie J; Yam JY; Yen PH; Gray D; Motta V; Elford AR; DeLuca S; Wang L; Effendi S; Ellenchery R; Hirano N; Ohashi PS; Butler MO
Cancer Immunol Immunother; 2019 May; 68(5):773-785. PubMed ID: 30747243
[TBL] [Abstract][Full Text] [Related]
3. Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.
Andersen R; Donia M; Ellebaek E; Borch TH; Kongsted P; Iversen TZ; Hölmich LR; Hendel HW; Met Ö; Andersen MH; Thor Straten P; Svane IM
Clin Cancer Res; 2016 Aug; 22(15):3734-45. PubMed ID: 27006492
[TBL] [Abstract][Full Text] [Related]
4. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
[TBL] [Abstract][Full Text] [Related]
5. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.
Dudley ME; Yang JC; Sherry R; Hughes MS; Royal R; Kammula U; Robbins PF; Huang J; Citrin DE; Leitman SF; Wunderlich J; Restifo NP; Thomasian A; Downey SG; Smith FO; Klapper J; Morton K; Laurencot C; White DE; Rosenberg SA
J Clin Oncol; 2008 Nov; 26(32):5233-9. PubMed ID: 18809613
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant adoptive immunotherapy with tumour-infiltrating lymphocytes and modulated doses of interleukin-2 in 22 patients with melanoma, colorectal and renal cancer, after radical metastasectomy, and in 12 advanced patients.
Ridolfi R; Flamini E; Riccobon A; De Paola F; Maltoni R; Gardini A; Ridolfi L; Medri L; Poletti G; Amadori D
Cancer Immunol Immunother; 1998 Jun; 46(4):185-93. PubMed ID: 9671141
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis.
Dafni U; Michielin O; Lluesma SM; Tsourti Z; Polydoropoulou V; Karlis D; Besser MJ; Haanen J; Svane IM; Ohashi PS; Kammula US; Orcurto A; Zimmermann S; Trueb L; Klebanoff CA; Lotze MT; Kandalaft LE; Coukos G
Ann Oncol; 2019 Dec; 30(12):1902-1913. PubMed ID: 31566658
[TBL] [Abstract][Full Text] [Related]
8. Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients.
Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Schallmach E; Kubi A; Shalmon B; Hardan I; Catane R; Segal E; Markel G; Apter S; Nun AB; Kuchuk I; Shimoni A; Nagler A; Schachter J
J Immunother; 2009 May; 32(4):415-23. PubMed ID: 19342963
[TBL] [Abstract][Full Text] [Related]
9. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.
Dudley ME; Wunderlich JR; Yang JC; Sherry RM; Topalian SL; Restifo NP; Royal RE; Kammula U; White DE; Mavroukakis SA; Rogers LJ; Gracia GJ; Jones SA; Mangiameli DP; Pelletier MM; Gea-Banacloche J; Robinson MR; Berman DM; Filie AC; Abati A; Rosenberg SA
J Clin Oncol; 2005 Apr; 23(10):2346-57. PubMed ID: 15800326
[TBL] [Abstract][Full Text] [Related]
10. Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma.
Dudley ME; Gross CA; Somerville RP; Hong Y; Schaub NP; Rosati SF; White DE; Nathan D; Restifo NP; Steinberg SM; Wunderlich JR; Kammula US; Sherry RM; Yang JC; Phan GQ; Hughes MS; Laurencot CM; Rosenberg SA
J Clin Oncol; 2013 Jun; 31(17):2152-9. PubMed ID: 23650429
[TBL] [Abstract][Full Text] [Related]
11. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies.
Besser MJ; Shapira-Frommer R; Itzhaki O; Treves AJ; Zippel DB; Levy D; Kubi A; Shoshani N; Zikich D; Ohayon Y; Ohayon D; Shalmon B; Markel G; Yerushalmi R; Apter S; Ben-Nun A; Ben-Ami E; Shimoni A; Nagler A; Schachter J
Clin Cancer Res; 2013 Sep; 19(17):4792-800. PubMed ID: 23690483
[TBL] [Abstract][Full Text] [Related]
12. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients.
Radvanyi LG; Bernatchez C; Zhang M; Fox PS; Miller P; Chacon J; Wu R; Lizee G; Mahoney S; Alvarado G; Glass M; Johnson VE; McMannis JD; Shpall E; Prieto V; Papadopoulos N; Kim K; Homsi J; Bedikian A; Hwu WJ; Patel S; Ross MI; Lee JE; Gershenwald JE; Lucci A; Royal R; Cormier JN; Davies MA; Mansaray R; Fulbright OJ; Toth C; Ramachandran R; Wardell S; Gonzalez A; Hwu P
Clin Cancer Res; 2012 Dec; 18(24):6758-70. PubMed ID: 23032743
[TBL] [Abstract][Full Text] [Related]
13. Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study.
Chandran SS; Somerville RPT; Yang JC; Sherry RM; Klebanoff CA; Goff SL; Wunderlich JR; Danforth DN; Zlott D; Paria BC; Sabesan AC; Srivastava AK; Xi L; Pham TH; Raffeld M; White DE; Toomey MA; Rosenberg SA; Kammula US
Lancet Oncol; 2017 Jun; 18(6):792-802. PubMed ID: 28395880
[TBL] [Abstract][Full Text] [Related]
14. A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma.
Poschke I; Lövgren T; Adamson L; Nyström M; Andersson E; Hansson J; Tell R; Masucci GV; Kiessling R
Cancer Immunol Immunother; 2014 Oct; 63(10):1061-71. PubMed ID: 24993563
[TBL] [Abstract][Full Text] [Related]
15. Adoptive immunotherapy with tumor-infiltrating lymphocytes and subcutaneous recombinant interleukin-2 plus interferon alfa-2a for melanoma patients with nonresectable distant disease: a phase I/II pilot trial. Melanoma Istituto Scientifico Tumori Group.
Queirolo P; Ponte M; Gipponi M; Cafiero F; Peressini A; Semino C; Pietra G; Lionetto R; Vecchio S; Ribizzi I; Melioli G; Sertoli MR
Ann Surg Oncol; 1999; 6(3):272-8. PubMed ID: 10340886
[TBL] [Abstract][Full Text] [Related]
16. Adoptive immunotherapy of advanced melanoma patients with interleukin-2 (IL-2) and tumor-infiltrating lymphocytes selected in vitro with low doses of IL-2.
Arienti F; Belli F; Rivoltini L; Gambacorti-Passerini C; Furlan L; Mascheroni L; Prada A; Rizzi M; Marchesi E; Vaglini M
Cancer Immunol Immunother; 1993 May; 36(5):315-22. PubMed ID: 8477417
[TBL] [Abstract][Full Text] [Related]
17. CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma.
Dudley ME; Gross CA; Langhan MM; Garcia MR; Sherry RM; Yang JC; Phan GQ; Kammula US; Hughes MS; Citrin DE; Restifo NP; Wunderlich JR; Prieto PA; Hong JJ; Langan RC; Zlott DA; Morton KE; White DE; Laurencot CM; Rosenberg SA
Clin Cancer Res; 2010 Dec; 16(24):6122-31. PubMed ID: 20668005
[TBL] [Abstract][Full Text] [Related]
18. Treatment with tumour infiltrating lymphocytes and interleukin-2 in patients with metastatic melanoma: a pilot study.
Baars JW; Fonk JC; Scheper RJ; von Blomberg-van der Flier BM; Bril H; von Valk P; Pinedo HM; Wagstaff J
Biotherapy; 1992; 4(4):289-97. PubMed ID: 1622742
[TBL] [Abstract][Full Text] [Related]
19. Tumor infiltrating lymphocytes and continuous infusion interleukin-2 after metastasectomy in 61 patients with melanoma, colorectal and renal carcinoma.
Fabbri M; Ridolfi R; Maltoni R; Ridolfi L; Riccobon A; Flamini E; De Paola F; Verdecchia GM; Amadori D
Tumori; 2000; 86(1):46-52. PubMed ID: 10778766
[TBL] [Abstract][Full Text] [Related]
20. Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response.
Pockaj BA; Sherry RM; Wei JP; Yannelli JR; Carter CS; Leitman SF; Carasquillo JA; Steinberg SM; Rosenberg SA; Yang JC
Cancer; 1994 Mar; 73(6):1731-7. PubMed ID: 8156501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
